Skip to main content

File photo of Valeant Pharmaceuticals International Inc. CEO Michael Pearson.

Ryan Remiorz/THE CANADIAN PRESS

Valeant Pharmaceuticals International Inc.'s apparent victory in the bidding war for skin-care company Obagi Medical Products Inc. should strengthen its presence in the dermatology segment and open the door to further geographical expansion.

Montreal-based Valeant sweetened its offer for California-based Obagi Medical Products Inc. to $24 (U.S.) in cash per share from $$19.75 last week after its initial bid was trumped by an all-cash $22-per-share proposal from Merz Pharma Group.

Merz said on Monday it's withdrawing from the bidding war, saying it isn't comfortable pursuing the acquisition at these levels.

Story continues below advertisement

"Merz is a disciplined buyer and at this level the economics of such a transaction do not meet our requirements," chief executive officer Philip Burchard said in a news release.

Canaccord Genuity analyst Neil Maruoka says he'd be surprised to see another rival bid surface.

Obagi no doubt represented a choice opportunity for privately held German firm Merz to gain a foothold in the U.S. market, he said.

"But, with Valeant's dominant position in dermatology and its integration capabilities and ability to drive synergies, there was probably a view that they didn't have the same capacities to drive value," he said.

If the deal goes through for Valeant, it will be a "nice tuck-in for them. This represents all the characteristics they look for in a dermatology acquisition and presents opportunities outside the U.S., like Asia," said Mr. Maruoka.

Valeant, Canada's largest publicly traded drug company, unveiled its $343.8-million offer for Obagi last month. At the initial price of $19.75 per share, the bid represented a 28-per-cent premium to Obagi's closing price on Nasdaq on March 19.

At the revised $24-per-share price, the proposed transaction is valued at about $418-million.

Story continues below advertisement

Valeant said when it first announced its proposal that the merger would provide annual cost synergies of at least $40-million.

Formerly Biovail Corp., Valeant made more than a dozen acquisitions last year, including the $2.6-billion takeover of Medicis Pharmaceutical Corp. of Scottsdale, Ariz., a maker of skin-care products.

Obagi's biggest revenue generators are its Nu Derm anti-aging and acne treatment products.

Based in Long Beach, Calif., Obagi posted revenue of $120-million last year.

Report an error Editorial code of conduct
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter